




PHARMACEUTICALS DISCOVERED WITH AI



ARTIFICIAL INTELLIGENCE FOR DISCOVERY SCIENCE  
FEBRUARY 2021


# AI HAS BEEN AROUND FOR DECADES



# AI PREDICTS EVENTS USING REAL WORLD DATA




*Collect Weather Data*



**AI**

*Process*




MON

TUE

WED

*Weather Prediction*

# AI APPLICATIONS IN DRUG DISCOVERY & DEVELOPMENT



| Source: Tufts Center for the Study of Drug Development, Pharmaceutical Research and Manufacturers of America

## OUR PRODUCTS / *NEW MEDICINES FOR COMPLEX DISEASE*

### First-In-Class

New Biology In Disease

### Small Molecule

90% of Today's Medications

# CASE STUDY: SYSTEMIC LUPUS ERYTHEMATOSUS (LUPUS)

## Market

# 5 Million

Cases Worldwide

# Pain

Fatigue / Inflammation / Fever

# NSAIDs

Standard of Care  
With Limited Efficacy

## Opportunity

TXR-711 & TXR-712 *in vivo* Highlights


- Improved tolerability over rescue therapy
- Novel MOAs in Lupus
- Significant decrease in inflammation
- Significant improved kidney function

# \$2B


2024 Market  
(\$/Year)<sup>1</sup>

<sup>1</sup> Pharmaceutical Intelligence Services, GlobalData LLC

# DISCOVERY PROCESS / CANDIDATES TXR-711 & TXR-712 IDENTIFIED WITHIN 3 MONTHS





# SIGNIFICANT DECREASE IN INFLAMMATION / WITH UNOPTIMIZED COMPOUNDS



Glomerulonephritis and tubule basophilia – renal Inflammation measures

# SIGNIFICANT IMPROVED KIDNEY FUNCTION / WITH UNOPTIMIZED COMPOUNDS



Score	mg/dL
0	None
1	1-29
2	30-99
3	100-299
4	300-1999
5	≥2000

BUN and proteinuria – measure renal function efficacy

# PIPELINE / 18+ ACTIVE PROGRAMS




DISEASE AREA	DISCOVERY	PRECLINICAL	IND-ENABLING	PHASE 1
<b>Fibrotic</b>				
Chronic Kidney Disease (CKD)				
Idiopathic Pulmonary Fibrosis (IPF)				
Nonalcoholic Steatohepatitis (NASH)				
Endometriosis				
<b>Immunology/Inflammatory</b>				
Lupus (SLE)				
Undisclosed Imm2				
Undisclosed Imm3				
Undisclosed Inf1				
<b>Oncology</b>				
Glioblastoma				
Liver Cancer (HCC)				
Lung Cancer (NSCLC)				
Undisclosed Onc4				
Undisclosed Onc5				
Undisclosed Onc6				
Undisclosed Onc7				
Undisclosed Onc8				
<b>Other</b>				
Glaucoma				
Undisclosed Meta2				
Undisclosed Neuro1				
Undisclosed Meta1				

Key
twoXAR
Partnered

# PARTNERSHIP OPPORTUNITIES

## Rapidly Launch New Disease Areas

- New Biology / Discovery
- Preclinical & Scientific Guidance
- KOL & CRO Connections



## PARTNER BENEFIT

# Save Years

From zero to *in vivo*

# 30x Success

Screen 10-15 Hits



PHARMACEUTICALS DISCOVERED WITH AI



Andrew A. Radin, CEO  
[aradin@twoxar.com](mailto:aradin@twoxar.com)